戻る Agenda
Session 4: Brexit - the impact on pharmacogivilance activities
Session Chair(s)
Peter De Veene, MD
GQPPV
MSD Belgium, Belgium
On 29 March 2017, the United Kingdom (UK) notified the European Council of its intention to withdraw from the European Union (EU), a process known as 'Brexit'. In this session, we will explore the implications of this Brexit on the pharmaceutical industry and in particular the consequences for the pharmacovigilance area, both in terms of regulatory system as well as the impact on companies. We will hear both from the regulators and industry how these changes might impact us and how we can prepare to minimize the impact after the UK leaves the EU on 30 March 2019. There will be a Q&A session to follow.
Speaker(s)
Q&A
Vicki Edwards, RPh
Abbvie, United Kingdom
Vice President, Pharmacovigilance Excellence and International QPPV
The future of Pharmacovigilance systems in UK after Brexit
Mick Foy
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Director of Delivery
Agnès Saint-Raymond, DrMed
European Medicines Agency, Netherlands
Head of Division International Affairs